VivoSim Labs, Inc.(VIVS)Earnings, Financials & Key Ratios

VIVS•NASDAQ

$0.90

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryRegenerative Medicine and Tissue Engineering

AboutVivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.Show more

Revenue$144K+32.1%
EBITDA-$12M+16.6%
Net Income-$2M+83.0%
EPS (Diluted)-1.70+91.2%
Gross Margin96.53%-3.5%
EBITDA Margin-8576.39%+36.9%
Operating Margin-8761.11%+36.7%
Net Margin-1727.78%+87.2%
ROE-35.31%+77.2%

VIVS Price & Volume

VivoSim Labs, Inc. (VIVS) stock price & volume — 10-year historical chart

Loading chart...

Persistent Cash Burn Threatens Clinical Development Viability

Investment Thesis • Updated 2026Q3

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Binary clinical trial failure

Key Thesis Takeaways

VivoSim Labs remains a pre-commercial biotechnology entity characterized by nominal revenue generation and a reliance on non-operating income to mask core operational deficits.
The company's long-term value proposition is severely constrained by a rapidly depleting cash position and the absence of a scalable commercial product.
Investors should monitor the firm's ability to secure non-dilutive financing, as the current trajectory suggests an imminent risk of insolvency given the ongoing quarterly losses.

Verdict Logic

the company's cash runway is nearing a critical threshold with a $4.3 million balance as of 2026Q3, which may necessitate highly dilutive financing to sustain operations.

VIVS Growth Metrics

VivoSim Labs, Inc. (VIVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-12.87%

5 Years-42.01%

3 Years-54.21%

TTM16.39%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM90.09%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM91.43%

Return on Capital

10 Years-79.25%

5 Years-92.61%

3 Years-126.55%

Last Year-163.82%

Latest VIVS News

Recent stock market news and headlines for VivoSim Labs, Inc. (VIVS)

Globe News Wire·Jun 29, 2026

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced that data demonstrating the power of its advanced 3D human tissue models will be featured in two presentations at the European Society of Toxicology's annual conference.

GlobeNewsWire·Jun 29, 2026

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs) VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)

Peers Comparison

Key metrics vs top competitors for VivoSim Labs, Inc. (VIVS)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
VIVSVivoSim Labs, Inc.Current	$0.90	$2.36M	-0.53	32.11%	-1727.78%	-35.31%	—
IMNMImmunome, Inc.	$24.39	$2.33B	-10.04	-23.23%	-5593.85%	-51.15%	—
PRAXPraxis Precision Medicines, Inc.	$323.95	$9.36B	-24.03	-100%	—	-43.02%	—
KYMRKymera Therapeutics, Inc.	$119.24	$9.74B	-32.31	-16.72%	-612.17%	-25.02%	—
RXRXRecursion Pharmaceuticals, Inc.	$3.84	$1.72B	-2.67	26.92%	-844.46%	-54.32%	—
SDGRSchrödinger, Inc.	$16.49	$1.23B	-11.70	23.29%	-40.6%	-30.85%	—

Compare VIVS vs Peers

VivoSim Labs, Inc. (VIVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMNM

Most directly comparable listed peer for VIVS.

Scale Benchmark

vs NVDA

Larger-name benchmark to compare VIVS against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMNM, PRAX, KYMR, RXRX

Get notified when VIVS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

VIVS Frequently Asked Questions

VivoSim Labs, Inc. (VIVS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is VivoSim Labs, Inc.'s revenue?

VivoSim Labs, Inc. (VIVS) reported $0.1M in revenue for fiscal year 2025.

How fast is VivoSim Labs, Inc. growing?

VivoSim Labs, Inc. (VIVS) grew revenue by 32.1% over the past year. This is strong growth.

Is VIVS profitable?

VivoSim Labs, Inc. (VIVS) reported a net loss of $1.2M for fiscal year 2025.

Dividend & Returns

What is VIVS's return on equity?

VivoSim Labs, Inc. (VIVS) has a return on equity (ROE) of -35.3%. Negative ROE indicates the company is unprofitable.

What is VivoSim Labs, Inc.'s free cash flow?

VivoSim Labs, Inc. (VIVS) had negative free cash flow of $10.6M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in VIVS back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

VIVSVivoSim Labs, Inc.Current

$0.90

$2.36M

-0.53

32.11%

-1727.78%

-35.31%

—

IMNMImmunome, Inc.

$24.39

$2.33B

-10.04

-23.23%

-5593.85%

-51.15%

—

PRAXPraxis Precision Medicines, Inc.

$323.95

$9.36B

-24.03

-100%

—

-43.02%

—

KYMRKymera Therapeutics, Inc.

$119.24

$9.74B

-32.31

-16.72%

-612.17%

-25.02%

—

RXRXRecursion Pharmaceuticals, Inc.

$3.84

$1.72B

-2.67

26.92%

-844.46%

-54.32%

—

SDGRSchrödinger, Inc.

$16.49

$1.23B

-11.70

23.29%

-40.6%

-30.85%

—